Race Oncology Limited
ASX:RAC.AX
Overview | Financials
Company Name | Race Oncology Limited |
Symbol | RAC.AX |
Currency | AUD |
Price | 1.575 |
Market Cap | 268,494,975 |
Dividend Yield | 0% |
52-week-range | 0.64 - 2.09 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Peter M. Smith Ph.D. |
Website | https://www.raceoncology.com |
An error occurred while fetching data.
About Race Oncology Limited
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD